- Molecular NameDoxylamine
- SynonymDossilamina [DCIT]; Doxilminio [INN-Spanish]; Doxylaminum [INN-Latin]
- Weight270.376
- Drugbank_IDDB00366
- ACS_NO469-21-6
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)2.69
- pka4.4, 9.2
- LogD (pH=7, predicted)1.0
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-0.43
- LogSw (predicted, AB/LogsW2.0)0.4
- Sw (mg/ml) (predicted, ACD/Labs)2.35
- No.of HBond Donors0
- No.of HBond Acceptors3
- No.of Rotatable Bonds6
- TPSA25.36
- StatusFDA approved
- AdministrationN/A
- PharmacologyOne of the many sedating antihistamines used by itself as a short-term sedative, in combination with other drugs as a night-time cold and allergy relief drug, in combination with the analgesics paracetamol and codeine as an analgesic / calmative preparation, and is prescribed in combination with vitamin B6 (pyridoxine) to prevent morning sickness in pregnant women.
- Absorption_valueN/A
- Absorption (description)Readily absorbed via the gastrointestinal tract.
- Caco_2N/A
- Bioavailability24.7
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic. The two main metabolites are desmethyldoxylamine and didesmethyldoxylamine.
- Half lifevariable; 6~12 h
- ExcretionUrine (primarily as metabolites)
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityDoxylamine succinate is generally safe for administration to healthy adults. Typical preparations that contain doxylamine range from 6.25 mg to 25.0 mg. The LD50 is estimated to be 50–500 mg/kg in humans. Symptoms of overdose may include dry mouth, dilated pupils, insomnia, euphoria, hallucinations, seizures, rhabdomyolysis, and death. Fatalities, while rare, have been recorded. Rarely, an overdose results in rhabdomyolysis and acute renal failure.
- LD50 (rat)N/A
- LD50 (mouse)N/A